88 related articles for article (PubMed ID: 12503816)
1. ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.
Hilger RA; Kredke S; Hedley D; Moeller JG; Bauer RJ; Stellberg W; Seeber S; Scheulen ME; Strumberg D
Int J Clin Pharmacol Ther; 2002 Dec; 40(12):567-8. PubMed ID: 12503816
[No Abstract] [Full Text] [Related]
2. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.
Strumberg D; Voliotis D; Moeller JG; Hilger RA; Richly H; Kredtke S; Beling C; Scheulen ME; Seeber S
Int J Clin Pharmacol Ther; 2002 Dec; 40(12):580-1. PubMed ID: 12503822
[No Abstract] [Full Text] [Related]
3. Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.
Hilger RA; Kredtke S; Scheulen ME; Seeber S; Strumberg D
Int J Clin Pharmacol Ther; 2004 Nov; 42(11):648-9. PubMed ID: 15598034
[No Abstract] [Full Text] [Related]
4. Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf.
Matsuzawa Y; Kiuchi Y; Toyomura K; Matsumoto I; Nakamura H; Fujino H; Murayama T; Kawashima T
J Pharmacol Sci; 2009 Oct; 111(2):182-92. PubMed ID: 19783865
[TBL] [Abstract][Full Text] [Related]
5. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Wilhelm SM; Carter C; Tang L; Wilkie D; McNabola A; Rong H; Chen C; Zhang X; Vincent P; McHugh M; Cao Y; Shujath J; Gawlak S; Eveleigh D; Rowley B; Liu L; Adnane L; Lynch M; Auclair D; Taylor I; Gedrich R; Voznesensky A; Riedl B; Post LE; Bollag G; Trail PA
Cancer Res; 2004 Oct; 64(19):7099-109. PubMed ID: 15466206
[TBL] [Abstract][Full Text] [Related]
6. Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors.
Clin Colorectal Cancer; 2003 May; 3(1):16-8. PubMed ID: 12777188
[No Abstract] [Full Text] [Related]
7. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
8. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Mross K; Steinbild S; Baas F; Reil M; Buss P; Mersmann S; Voliotis D; Schwartz B; Brendel E
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):618-9. PubMed ID: 14692719
[No Abstract] [Full Text] [Related]
9. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.
Plaza-Menacho I; Mologni L; Sala E; Gambacorti-Passerini C; Magee AI; Links TP; Hofstra RM; Barford D; Isacke CM
J Biol Chem; 2007 Oct; 282(40):29230-40. PubMed ID: 17664273
[TBL] [Abstract][Full Text] [Related]
10. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
Prazeres H; Couto JP; Rodrigues F; Vinagre J; Torres J; Trovisco V; Martins TC; Sobrinho-Simões M; Soares P
Endocr Relat Cancer; 2011 Aug; 18(4):401-12. PubMed ID: 21551259
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.
Heim M; Sharifi M; Hilger RA; Scheulen ME; Seeber S; Strumberg D
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):616-7. PubMed ID: 14692718
[No Abstract] [Full Text] [Related]
12. Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
Karhoff D; Sauer S; Schrader J; Arnold R; Fendrich V; Bartsch DK; Hörsch D
Neuroendocrinology; 2007; 85(1):45-53. PubMed ID: 17341847
[TBL] [Abstract][Full Text] [Related]
13. Circadian rhythm in the regulation of the MAP kinase pathway--pitfall in the determination of surrogate parameters?
Hilger RA; Díaz-Carballo D; Bauer S; Kredtke S; Scheulen ME; Seeber S; Strumberg D
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):614-5. PubMed ID: 14692717
[No Abstract] [Full Text] [Related]
14. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication.
Himmelsbach K; Sauter D; Baumert TF; Ludwig L; Blum HE; Hildt E
Gut; 2009 Dec; 58(12):1644-53. PubMed ID: 19710032
[TBL] [Abstract][Full Text] [Related]
15. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
Richly H; Kupsch P; Passage K; Grubert M; Hilger RA; Kredtke S; Voliotis D; Scheulen ME; Seeber S; Strumberg D
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):620-1. PubMed ID: 14692720
[No Abstract] [Full Text] [Related]
16. BAY 43-9006: preclinical data.
Wilhelm S; Chien DS
Curr Pharm Des; 2002; 8(25):2255-7. PubMed ID: 12369853
[TBL] [Abstract][Full Text] [Related]
17. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
18. C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Jilaveanu LB; Zito CR; Aziz SA; Conrad PJ; Schmitz JC; Sznol M; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2009 Sep; 15(18):5704-13. PubMed ID: 19737955
[TBL] [Abstract][Full Text] [Related]
19. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
20. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Jilaveanu L; Zito C; Lee SJ; Nathanson KL; Camp RL; Rimm DL; Flaherty KT; Kluger HM
Clin Cancer Res; 2009 Feb; 15(3):1076-85. PubMed ID: 19188183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
